Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors (RMD Open (2018) 4 (e000692)) DOI: 10.1136/rmdopen-2018-000692)

P. Nash, F. Behrens, A. Orbai

Research output: Contribution to journalComment/debatepeer-review

Abstract

Nash P, Behrens F, Orbai A, et al. Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors. RMD Open 2018;4:e000692. doi: 10.1136/ rmdopen-2018-000692 This article has been corrected since it first published. There were some copyediting errors which have been rectified now.

Original languageEnglish (US)
Article numbere000692corr1
JournalRMD Open
Volume5
Issue number1
DOIs
StatePublished - Feb 1 2019

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Fingerprint Dive into the research topics of 'Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors (RMD Open (2018) 4 (e000692)) DOI: 10.1136/rmdopen-2018-000692)'. Together they form a unique fingerprint.

Cite this